Linezolid Mylan

Linezolid, the active ingredient in Linezolid Mylan, is an oxazolidinone presented as an oral tablet for oral use. It is indicated for the treatment of complicated skin and soft‑tissue infections, community‑acquired bacterial pneumonia, methicillin‑resistant Staphylococcus aureus (MRSA) infections and vancomycin‑resistant Enterococcus (VRE) infections in adult patients. The drug achieves bacterial eradication by binding to the 50S ribosomal subunit, thereby inhibiting protein synthesis.

GNH USA supplies Linezolid Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibacterial that is used to treat infections caused by susceptible Gram‑positive bacteria.

- Complicated skin and soft‑tissue infections: improves clinical cure rates by targeting MRSA and other resistant Gram‑positive organisms. - Community‑acquired bacterial pneumonia: provides effective coverage against Streptococcus pneumoniae and atypical pathogens. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves bacterial eradication where β‑lactams are ineffective. - Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative oral option for resistant enterococcal disease.

Linezolid may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may be watery. - Headache: transient cranial discomfort. - Metallic taste: altered taste sensation in the mouth. - Vomiting: occasional expulsion of stomach contents. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, increasing bleeding risk. - Peripheral neuropathy: tingling or numbness in extremities. - Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents. - Optic neuritis: inflammation of the optic nerve that may affect vision. - Lactic acidosis: buildup of lactic acid causing metabolic disturbance. - Myelosuppression: suppression of bone‑marrow activity leading to anemia or leukopenia.

When prescribing Linezolid, clinicians should consider several precautionary measures to minimize risk.

- Renal impairment: dose adjustment may be required and renal function should be monitored. - Hepatic impairment: use with caution; monitor liver enzymes during therapy. - Hematologic monitoring: regular complete blood counts are advised to detect thrombocytopenia or anemia. - Concomitant serotonergic agents: avoid co‑administration due to risk of serotonin syndrome. - Pregnancy and lactation: safety not established; use only if potential benefit justifies potential risk. - Store below 25°C: keep in the original pack, protect from moisture.

Linezolid can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use can cause hypertensive crisis. - Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, tramadol): may precipitate serotonin syndrome. - Pimozide: risk of QT prolongation and arrhythmia; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, potentially lowering linezolid concentrations. - Antacids containing magnesium or aluminum: may decrease absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR as linezolid may enhance anticoagulant effect. - Digoxin: observe serum levels for possible increase.